- Global Pharma News & Resources

Global Radiation Syndrome Treatment Market (2019-2023) by Disease and Region - Key Players are Amgen, Neumedicines, Partner Therapeutics, Tonix Pharmaceuticals, and Onconova Therapeutics -

The "Global Radiation Syndrome Treatment Market 2019-2023" report has been added to's offering.

The radiation syndrome treatment market will register a CAGR of more than 6% by 2023.

The latest trend gaining momentum in the market is the advent of regenerative therapy. According to the report, one of the major drivers for this market is the increase in nuclear testing. Further, the report states that one of the major factors hindering the growth of this market is the difficulty to diagnose radiation syndrome.

The advent of regenerative therapy is expected to help the market grow. The global radiation syndrome treatment market has seen strong advances in terms of treatment options. The advent of regenerative medicines such as stem-cell therapy is one among such advances. In stem-cell therapy, the stem cells are taken from the patient and are re-inserted to replace the damaged cells to treat or prevent a disease.

The increasing nuclear testing in South-East Asia in recent years has resulted in the rise in the symptoms of radiation toxicity and exposure in nearby countries. also, various scientists and pharmaceutical companies believe that the increasing testing of nuclear launches cause significant damage to the environment.

Key Players

  • Amgen
  • Neumedicines
  • Partner Therapeutics
  • Tonix Pharmaceuticals
  • Onconova Therapeutics

Topics Covered

1. Executive Summary

2. Scope of the Report

3. Market Landscape

4. Market Sizing

5. Five Forces Analysis

6. Market Segmentation by Disease

7. Customer Landscape

8. Geographic Landscape

9. Decision Framework

10. Drivers and Challenges

11. Market Trends

12. Vendor Landscape

13. Vendor Analysis

For more information about this report visit

View source version on

Editor Details

Last Updated: 06-Dec-2018